No Data
No Data
The pharmaceutical company Cornerstone Pharmaceuticals-B (02616.HK) has received approval from the National Medical Products Administration for the registration of the listing of the drug Taijihua (Afatinib Tablets) 100mg, which was transferred from overs
On August 15th, Grontmij released a statement that the domestically-produced version of Taijihuahua (Afatnib 100mg tablet) has been approved by the National Medical Products Administration of China (NMPA) for market registration. Following the approval of the 300mg specification in June 2024, the approval of the 100mg specification further enriches the medication choices of Taijihuahua. Both specifications are expected to gradually replace existing imported products by the end of 2024 or early 2025 and achieve domestic supply. The CEO and R&D Chief of Grontmij
Express News | CStone Pharmaceuticals - Approval of Manufacturing Localization Registration Application for Ayvakit- (Avapritinib Tablets, 100 Mg) by China Nmpa
Chismed Pharma Group Inc. - B (02616.HK) plans to hold a board of directors meeting on August 23 to review the interim results.
Cornerstone Pharmaceuticals-B (02616.HK) announced on August 12 that the board of directors meeting will be held on Friday, August 23, 2024 to consider and approve the unaudited mid-term performance of the company and its subsidiaries for the six months ending on June 30, 2024, and to consider the distribution of interim dividends (if any).
CSTONE PHARMA-B: DATE OF BOARD MEETING
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
HK stocks jumped | CSPC Pharma-B (02616) rose more than 4% as the European Commission approved the use of sintilimab for first-line treatment of non-small cell lung cancer.
Biostone Pharmaceutical - B (02616) rose more than 4%, as of the time of publication, up 4.17%, reporting HKD 1.25, with a turnover of 0.941 million Hong Kong dollars.
No Data